1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

02 Aug 2024
Admin
News Article

Otsuka Pharmaceutical Announces Acquisition of Jnana Therapeutics

Overview

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jnana Therapeutics Inc. (Jnana) have announced a definitive merger agreement. Under this agreement, Otsuka will acquire Jnana through its subsidiary, Otsuka America, Inc. (OAI), making Jnana a wholly-owned subsidiary. The acquisition, valued at USD $800 million, is expected to close in the third quarter of fiscal 2024, pending customary closing conditions. Additional payments of up to USD $325 million may be made based on development and regulatory milestones.

Jnana's Chemoproteomics Technology

Jnana's RAPID platform, a next-generation chemoproteomics technology, enables the discovery of medicines for challenging-to-drug targets by leveraging high-throughput, binding-based screening to identify small molecules with diverse pharmacologies.
This platform has successfully produced first-in-class compounds for targets like solute carriers, transcription factors, and signaling scaffold proteins.
Jnana’s approach complements that of Astex Pharmaceuticals, an Otsuka subsidiary based in the UK.
Jnana focuses on PKU, a rare metabolic disorder, and autoimmune diseases.
Its lead candidate, JNT-517, an allosteric small molecule inhibitor of SLC6A19, has shown promise as a first-in-class oral treatment for PKU in Phase 1b/2 studies.
Jnana is also exploring treatments for autoimmune diseases targeting IRF3, a key transcription factor for interferon production.

Otsuka’s acquisition aligns with its strategic goal to expand its rare disease and specialty drug portfolio, complementing its work with Visterra, which advances antibody drug technology in the autoimmune field.

Jnana’s Operations

Jnana will continue its R&D operations as a wholly-owned subsidiary in Boston post-acquisition.
The transaction involves merging a special purpose company, established by OAI, into Jnana.
Shareholders of Jnana will receive cash consideration.
Completion is subject to Jnana shareholder approval and U.S. antitrust clearance, with an expected close in the third quarter of 2024.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!